Clinical Trials Browser

Lymphoma, Large B-Cell, Diffuse × fludarabine × 1 year × Clear all

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT06026319 2026-03-16

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01962636 2026-03-12

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Phase NA Recruiting

200 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Leukemia, Plasma Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT07284433 2026-03-12

QUADvance

Phase 1/2 Recruiting

178 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Large B-Cell, Diffuse

Clinical Trials

ALPHA3

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

QUADvance

ENABLE-2

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

Study of LYL314 in Aggressive Large B-Cell Lymphoma

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

ZUMA-7

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

GLEAN-1

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

FIRCE-1

DALY II USA/ MB-CART2019.1 for DLBCL

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting